Paper Details
- Home
- Paper Details
Impact of peroxisome proliferator activated receptor agonist drugs in a model of nephrotoxicity in rats.
Author: AliAzza A, El-RaoufOla M Abd, El-RhmanRana H Abd, GadAmany M, SaadEman B
Original Abstract of the Article :
Doxorubicin (DOX) is one of the basic anticancer drugs, nonetheless its use is restricted due to noxious side effects. Kidney failure is one of the main side effects that restrict its medical use. The current study assessed the nephroprotective effects of fenofibrate and pioglitazone against the ren...See full text at original site
Dr.Camel's Paper Summary Blogラクダ博士について
ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。
* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。
引用元：
https://doi.org/10.1002/jbt.23350
データ提供：米国国立医学図書館（NLM）
Peroxisome Proliferator Activated Receptor Agonists: A Potential Defense Against Doxorubicin-Induced Nephrotoxicity
Doxorubicin, a widely used anticancer drug, comes with a price: the risk of nephrotoxicity. This study investigates the potential nephroprotective effects of fenofibrate and pioglitazone, peroxisome proliferator activated receptor (PPAR) agonists, against doxorubicin-induced renal injury in rats. The researchers employed a controlled experimental design to assess the impact of these drugs on renal function, oxidative stress, inflammation, and apoptosis.
PPAR Agonists: A Promising Strategy for Nephroprotection
The study findings suggest that both fenofibrate and pioglitazone offer significant nephroprotective effects against doxorubicin-induced renal injury. Treatment with these PPAR agonists, either alone or in combination, effectively attenuated the harmful effects of doxorubicin, reducing oxidative stress, inflammation, and apoptosis. This suggests that PPAR agonists may hold potential as therapeutic agents for preventing or mitigating doxorubicin-induced kidney damage.
Navigating the Shifting Sands of Nephrotoxicity
Doxorubicin-induced nephrotoxicity can be a challenging complication, like navigating a desert with shifting sands. This research provides valuable insights into the potential role of PPAR agonists in protecting the kidneys from this harmful side effect. It suggests that these drugs could provide a valuable tool for managing doxorubicin therapy, ensuring a smoother and safer journey for patients.
Dr.Camel's Conclusion
This study sheds light on the potential benefits of PPAR agonists for mitigating doxorubicin-induced nephrotoxicity. The researchers demonstrate the effectiveness of these drugs in reducing oxidative stress, inflammation, and apoptosis, suggesting a promising strategy for safeguarding renal function in patients receiving doxorubicin therapy. Their work provides a glimmer of hope in the desert of nephrotoxicity, offering a potential solution for improving patient outcomes.
Date :
- Date Completed 2023-06-12
- Date Revised 2023-06-12
Further Info :
Related Literature
English
This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.